Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study-Reference-Cited by-同舟云学术

Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study

Published:2024-09-09 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Piraccini B. M.¹²^ORCID,Pampaloni F.¹²^ORCID,Cedirian S.¹²^ORCID,Quadrelli F.¹²,Bruni F.¹²^ORCID,Rapparini L.¹²^ORCID,Caro G.³^ORCID,Acri M. C.³,Ala L.³,Rossi A.³^ORCID,Pellacani G.³,Lacarrubba F.⁴^ORCID,Micali G.⁴,Dall'Oglio F.⁴,Vastarella M.⁵^ORCID,Cantelli M.⁵,Nappa P.⁵,Diluvio L.⁶^ORCID,Bianchi L.⁶,Gnesotto L.⁷^ORCID,Sechi A.⁸^ORCID,Naldi L.⁸,Tassone F.⁹¹⁰,Peris K.⁹¹⁰,Caldarola G.⁹¹⁰^ORCID,Pinto L. M.⁹¹⁰,Girolomoni G.¹¹^ORCID,Marangoni F.¹¹,Bellinato F.¹¹^ORCID,Gisondi P.¹¹^ORCID,Scandagli I.¹²,Prignano F.¹²^ORCID,Pimpinelli N.¹²,Tomasini C.¹³¹⁴,Barruscotti S.¹³¹⁴^ORCID,De Simoni E.¹⁵^ORCID,Simonetti O.¹⁵,Ambrogio F.¹⁶,Foti C.¹⁶,Boccaletti V.¹⁷,Fraghì A.¹⁷,Marzano A. V.¹⁸¹⁹^ORCID,Mattioli M. A.¹⁸¹⁹,Rocca L.¹⁸¹⁹,Barbareschi M.¹⁹,Ferrucci S. M.¹⁸,Gallo G.²⁰^ORCID,Ribero S.²⁰^ORCID,Quaglino P.²⁰^ORCID,Balestri R.²¹,Ioris T.²¹,Caposiena Caro R. D.²²,Zalaudek I.²²,Vagnozzi E.²³²⁴,Fargnoli M. C.²³²⁴^ORCID,Caponio C.²⁴^ORCID,Rubegni P.²⁵,Cinotti E.²⁵^ORCID,Trovato E.²⁵^ORCID,Romanelli M.²⁶,Dini V.²⁶^ORCID,Manzo Margiotta F.²⁶^ORCID,Feliciani C.²⁷^ORCID,de Felici del Giudice M. B.²⁷^ORCID,Atzori L.²⁸^ORCID,Sanna S.²⁸,Lembo S.²⁹,Raimondo A.²⁹^ORCID,Magnano M.³⁰^ORCID,Starace M.¹²^ORCID

Affiliation:

1. Dermatology Unit IRCCS Azienda Ospedaliero‐Universitaria di Bologna, Policlinico S. Orsola‐Malpighi Bologna Italy

2. Department of Medical and Surgical Sciences Alma Mater Studiorum University of Bologna Bologna Italy

3. Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences Sapienza University Rome Italy

4. Dermatology Clinic University of Catania Catania Italy

5. Dermatology Unit, Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

6. Dermatology Unit, Fondazione Policlinico di Tor Vergata University of Rome Tor Vergata Rome Italy

7. Dermatology Unit, Department of Medicine University of Padova Padova Italy

8. Dermatology Unit San Bortolo Hospital Vicenza Italy

9. UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A. Gemelli – IRCCS Rome Italy

10. Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale Università Cattolica del Sacro Cuore Rome Italy

11. Dipartimento di Medicina, Sezione di Dermatologia Università di Verona Verona Italy

12. Department of Health Sciences, Section of Dermatology University of Florence Florence Italy

13. Dermatology Clinic Fondazione IRCCS Policlinico san Matteo Pavia Italy

14. Department of Clinical‐Surgical, Diagnostic and Pediatric Sciences University of Pavia Pavia Italy

15. Dermatology Clinic‐Azienda Ospedaliero Universitaria delle Marche Ancona Italy

16. Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‐J) University of Bari “Aldo Moro” Bari Italy

17. Clinica Dermatologica Università degli Studi di Brescia Brescia Italy

18. Dermatology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

19. Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan Italy

20. Department of Medical Sciences, Section of Dermatology University of Turin Torino Italy

21. Division of Dermatology “U.O. Multizonale APSS” Trento Italy

22. Dermatology Clinic, Maggiore Hospital University of Trieste Trieste Italy

23. Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy

24. Dermatology Unit San Salvatore Hospital, ASL 1 Abruzzo Italy

25. Department of Medical, Surgical and Neurological Science, Dermatology Section University of Siena, S. Maria Alle Scotte Hospital Siena Italy

26. Dermatology Unit, Department of Clinical and Experimental Medicine University of Pisa Pisa Italy

27. Unit of Dermatology, Department of Medicine and Surgery University of Parma Parma Italy

28. Dermatology Unit, Department Medical Sciences and Public Health University of Cagliari Catania Italy

29. Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana” University of Salerno Salerno Italy

30. Unit of Dermatology Versilia Hospital Lido di Camaiore Lucca Italy

Abstract

AbstractBackgroundAlopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata.Materials and MethodsWe conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex‐16 and the Hospital Anxiety and Depression Scale (HADS), respectively.ResultsA total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop‐out were registered.ConclusionData on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20312

Reference14 articles.

1. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management

2. Alopecia areata: What’s new in the epidemiology, comorbidities, and pathogenesis?

3. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials

4. Common causes of hair loss – clinical manifestations, trichoscopy and therapy

5. Baricitinib for the Treatment of Alopecia Areata